N/A N=378 Study of BD Pre-filled Flush Syringes in China
Effectiveness and Safety of Pre-filled Flush Syringe
Primary: the Overall Performance for Flushing and / or Locking the Catheters. — 187; 185 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=65 Study to Evaluate an Aflibercept (EYLEA®) Prefilled Syringe
Chorioretinal Vascular Disease
Primary: Number of Aflibercept Injections Successfully Administered Utilizing the Prefilled Syringe (PFS) — 35; 29 Injections
Phase 3 N=397 Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients
Acute Gouty Arthritis
Primary: Pain Intensity on a 0-100 mm Visual Analog Scale (VAS) Between the Canakinumab 150 mg PFS and Triamcinolone Acetonide 40 mg Groups — 17.1; 32 Millimeters
Phase 1 N=71 Pharmacokinetics and Safety of BI 695501 Administered Via Prefilled Syringe or Autoinjector
Healthy
Primary: Maximum Measured Concentration of BI 695501 in Plasma (Cmax) — 3.79; 3.48 Micro-gram (µg) per milliliter (mL)
N/A N=68 Safety and Effectiveness Clinical Evaluation of Injectable Medical Devices
Aesthetic Dermatology
Primary: Performance — 97.6 percentage of participants
Phase 1 N=98 Comparison Bioequivalence Study: Pre-filled Syringe (Reference) Versus Auto-injection Device (Test)
Healthy
Primary: Area Under the Plasma Drug Concentration-time Curve From Time 0 to Infinity (AUC) — 1308; 1326 microgram *day/mL
Phase 3 N=35 Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)
Diabetic Macular Edema (DME) · Neovascular Age-Related Macular Degeneration (nAMD)
Primary: Number of 8 mg Aflibercept Injections Successfully Administered Utilizing the PFS — 35 injections
N/A N=270 Effectiveness and Safety of Princess FILLER Lidocaine in Correction of Nasolabial Folds (NLF)
Dermatological Non-Disease
Primary: Responder Status Based on Independent Evaluating Investigator Live Assessment at Week 24 - Full Analysis Dataset — 222; 221 Participants — p=<0.0001
N/A N=436 Maintaining Patency in Implanted Port Catheters
Obstruction; Catheter, Infusion Catheter (Vascular) · Catheter; Complications (Indwelling Catheter)
Primary: Number of Participants With First Complete Occlusion Within 1 Year — 5; 4 Participants
Phase 3 N=34 Study of the Safety of Brolucizumab 6 mg in Prefilled Syringe in Patients With Neovascular Age Related Macular Degeneration
Neovascular Age Related Macular Degeneration
Primary: The Safety of Brolucizumab 6 mg Delivered in Prefilled Syringe in Patients With Neovascular Age Related Macular Degeneration — 0; 0 Participants
Phase 1 N=162 Pharmacokinetics and Safety of BI 695501
Healthy
Primary: Area Under the Concentration-time Curve of BI 695501 in Plasma Over the Time Interval From 0 to 1368 Hours (AUC0-1368) After Administration Via PFS and AI. — 2100; 2150…
Phase 1 N=190 Pharmacokinetics, Safety, and Tolerability Study of the Pen and PFS of SB5 in Healthy Subjects
Healthy
Primary: Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf) — 2743.2; 2503.3 h·μg/mL
N/A N=437 Reciprocating Medical Devices - a Study of a New Safety Device
Osteoarthritis · Rheumatoid Arthritis · Trauma
Primary: Pain Using VAS (Visual Analogue Pain Scale) — 5.2; 6.2 cm
Phase 3 N=421 Compare Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept
Psoriasis
Primary: Participant Satisfaction With Injection Device Evaluated at Week 12 for Modified Intent-to-treat (mITT) Population — 8.9; 7.6 units on a scale — p=<0.001
Phase 3 N=35 A Study in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema to Evaluate the Safety of the Faricimab Prefilled Syringe
Neovascular Age-related Macular Degeneration · Diabetic Macular Edema
Primary: Percentage of Injection Procedures With Successful Completions on Critical Tasks Performed by Healthcare Providers in the Use of the Faricimab Prefilled Syringe…
Phase 3 N=21 Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in Multiple Sclerosis Subjects
Multiple Sclerosis
Primary: Percentage of Participants in the Main Subset With Overall Success Using the Avonex Single-Use Autoinjector — 89 percentage of participants
Phase 3 N=214 Study of Secukinumab With 2 mL Pre-filled Syringes
Psoriasis
Primary: Participants With Psoriasis Area and Severity Index (PASI) 75 Response After 12 Weeks of Treatment — 64; 1 participants — p=< 0.0001
Phase 3 N=116 Study to Assess Functionality, Reliability, and Performance of a Pre-filled Syringe With Benralizumab Administered at Home
Asthma
Primary: Number and Percentage of Patients/Caregivers Who Successfully Administered Benralizumab 30 mg Subcutaneously (SC) by Injection With an APFS at Home — 112; 108; 106…
Phase 3 N=149 Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen
Primary Hypercholesterolemia · Mixed Dyslipidemia
Primary: Percentage of Participants With Full Administration of Evolocumab at Both Weeks 2 and 4 — 96.0; 89.2 percentage of participants
Phase 2 N=84 The Usability and Injection Time of the Physiolis Syringe and Autoinjector in Rheumatoid Arthritis Patients
Rheumatoid Arthritis
Primary: Participants' Overall Satisfaction With the Drug Administration Experience Using the Physiolis Syringe/Autoinjector in Comparison to the Current Syringe/Autoinjector…
N/A N=86 Safety and Effectiveness Clinical Evaluation of Injectable Medical Devices Viscol
Aesthetic Dermatology
Primary: Performance at 1 Month Investigator Overall VISCOL Range — 77 Participants — p=<0.0001
N/A N=5 Quantitative Characterization of Safe Irrigation for Ventricular Shunt Catheters
Hydrocephaly
Primary: To Demonstrate That the Flusher Can be Primed, Connected, and Activated in a Sterile Clinical Setting Per the Instructions for Use by the Treating Investigator . — 4; 4…
N/A N=600 Prospective, Randomized Controlled Comparison of TERUMO SurFlash Plus Versus BD Insyte Autoguard in an Urban ED
Catheters · Catheterization, Peripheral
Primary: Number of Participants With First-skin Puncture Success — 244; 229 Participants
Early Phase 1 N=48 Users Study Of The Caverject Delivery System
Healthy
Primary: Delivery System Success Rate (DSSR) — 66.67; 66.67; 100.00; 100.00 percentage of participants
Phase 2 N=49 An Multicentre Clinical Study to Evaluate the Usability and Safety of the Pre-filled Pen and Pre-filled Syringe of SB5 in Subjects With Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: The Change in Injection Site Pain Score Using an 11-point Visual Numeric Scale — -0.35; -0.11 Difference (scores on a scale)
Phase 3 N=397 Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients
Acute Gouty Arthritis
Primary: Number of Participants Who Reported Adverse Events — 78; 65; 64 Participants
Phase 2 N=25 Safety and Efficacy of a Metallic Cannula Versus A Standard Needle for Soft Tissue Augmentation of the Nasolabial Folds
Wrinkles
Primary: Number of Participants With Haematoma — 10; 23; 6; 11 Participants — p=<0.0001
N/A N=160 Prospective Clinical Evaluation of BD Spinal Needles
Analgesia · Anesthesia
Primary: Primary Safety: Incidence of Post-dural Puncture Headache (PDPH). — 2.8 % of subjects with a PDPH
Phase 4 N=100 Study of Techniques of Subcutaneous Administration of Fluids Enabled by Human Recombinant Hyaluronidase
Dehydration
Primary: Technical Challenges — 2; 3; 2; 2 participants
N/A N=60 EpiFaith Syringe for Epidural Space Detection
Epidural Localization
Primary: Success of Epidural Localization — 18; 30; 0; 0 Participants